2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards model
2021
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial
Aminorroaya A, Tavolinejad H, Sadeghian S, Jalali A, Alaeddini F, Emkanjoo Z, Mollazadeh R, Bozorgi A, Oraii S, Kiarsi M, Shahabi J, Akbarzadeh M, Rahimi B, Joharimoghadam A, Mohsenizade A, Mohammadi R, Oraii A, Ariannejad H, Apakuppakul S, Ngarmukos T, Tajdini M. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. American Heart Journal 2021, 237: 5-12. PMID: 33689731, DOI: 10.1016/j.ahj.2021.03.002.Peer-Reviewed Original ResearchConceptsLifestyle modificationMulti-center randomized controlled trialQuality of lifeRandomized controlled trialsVasovagal syncopeCounter-pressure maneuversImprove QoLComparison of outcomesSecondary outcomesSyncopal episodesControlled trialsPrimary outcomeQoLRecurrence of vasovagal syncopeTrial backgroundAdverse drug reactionsSurvey questionnaireTreatment of vasovagal syncopeMinor adverse drug reactionsBackground of lifestyle modificationFollow-upCOMFORT trialsTreat syncopeMedicationOutcomes
2020
Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19
Soleimani A, Kazemian S, Saleh S, Aminorroaya A, Shajari Z, Hadadi A, Talebpour M, Sadeghian H, Payandemehr P, Sotoodehnia M, Bahreini M, Najmeddin F, Heidarzadeh A, Zivari E, Ashraf H. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. American Journal Of Hypertension 2020, 33: 1102-1111. PMID: 32920644, PMCID: PMC7543264, DOI: 10.1093/ajh/hpaa149.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorsIn-hospital outcomesAcute kidney injuryClinically suspected COVID-19Severe COVID-19Receptor blockersEffects of angiotensin receptor blockersWorld Health Organization interim guidanceBenefits of angiotensin-converting enzyme inhibitorsIn-hospital outcomes of patientsAssociated with poor in-hospital outcomesFollowed-up patientsPoor in-hospital outcomesOutcomes of patientsAngiotensin receptor blockersII receptor blockersRetrospective observational studyIn-hospital complicationsIncomplete medical recordsRisk of mortalityClinical suspicionInvasive ventilationHypertensive patientsKidney injuryThe association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study
Poorhosseini H, Tavolinejad H, Aminorroaya A, Soleimani H, Aasham O, Jalali A, Mohammadi A, Beigi S, Sadeghian S, Bagheri J, Tajdini M. The association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study. Journal Of Diabetes And Its Complications 2020, 34: 107713. PMID: 32900589, DOI: 10.1016/j.jdiacomp.2020.107713.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graftingOccurrence of MACEPost-CABG patientsCumulative doseSecondary prevention of coronary artery diseaseSecondary preventionCoronary artery bypass graft surgeryPrevention of coronary artery diseaseArtery bypass graft surgeryFamily history of T2DMDoses of statinsTime of surgeryAssociation of statinsType 2 diabetes mellitusComposite of deathOccurrence of type 2 diabetes mellitusAdverse cardiovascular eventsBenefits of statinsBypass graft surgeryHistory of hypertensionHistory of T2DMArtery bypass graftingBody mass indexCoronary artery diseaseProgression to diabetes